Document text
Principal Investigator: GREGORY E. SIMON
Organization: KAISER FOUNDATION RESEARCH INSTITUTE
Fiscal Year: 2024
Award: $818,413
Funding agency: National Institute of Mental Health
Half of people starting antidepressant medication experience no significant improvement with the first
medication prescribed, leading either to discouragement and dropout or months of trial-and-error. More
accurately matching individuals with specific medications could significantly increase treatment success.
While selecting antidepressant medication is one of the most common clinical decisions in mental health
and general medical care, actionable evidence to guide that decision is remarkably scarce. Matching
patients with specific medications remains no better than chance. We identify three key gaps in previous
research to personalize antidepressant selection. First, previous research has not clearly distinguished
predicting overall prognosis or nonspecific response from predicting specific response to specific
medications. Second, sample sizes have typically been inadequate to accurately detect differential
treatment response. Third, previous research has focused on response to a single episode of treatment,
and that is too “noisy” a clinical phenotype to support identification of useful endophenotypes.
We propose to address these limitations using data resources, informatics tools, and analytic
methods developed by the NIMH-funded Mental Health Research Network (MHRN). Records databases
include comprehensive and harmonized data concerning sociodemographic characteristics, past mental
health diagnoses and treatments, comorbid mental health or substance use disorders, concomitant
treatments, dose and duration of antidepressant exposure, and structured assessment of depression
symptoms at baseline and follow-up. We will assemble a database including over 500,000
antidepressant treatment episodes for over 200,000 patients treated since 2010 in order to:
1) Rigorously test core assumptions of previous research and treatment guidelines - Heterogeneity-of-
treatment-effects analyses will evaluate two common beliefs regarding antidepressant response:
a. Favorable or unfavorable prior response to a single medication predicts subsequent response
b. Prior response to a medication in a specific class predicts subsequent response to that class
2) Identify and validate decision rules to inform selection of antidepressant treatment based on patterns
of prior treatment response – Analyses will use machine learning methods (dynamic weighted
ordinary least squares regression) to identify and validate practical decision rules for clinical practice.
3) Identify valid treatment response phenotypes to enable future research regarding genomic- or
biomarker-guided personalization – Primary analyses will use k-means clustering to identify patterns
of response across medications and medication classes. Additional analyses will explore clinical
characteristics that distinguish response phenotypes as well as order effects. Findings will inform a
next generation of research regarding genetic- and biomarker-guided antidepressant treatment.
Terms: <Active Follow-up><Address><Belief><Biological Markers><Caring><Characteristics><Clinical><Data><Data Bases><Databases><Diagnosis><Disease remission><Dose><Dropout><Drug Prescribing><Drug Prescriptions><Drugs><Emotional Depression><Funding><Future><Genetic><Genomics><Health system><Heterogeneity><Image><Individual><Intervention><Intervention Strategies><Least Squares><Least-Squares Analyses><Least-Squares Analysis><Machine Learning><Medical><Medication><Mental Health><Mental Hygiene><NIMH><National Institute of Mental Health><Patients><Pattern><Persons><Pharmaceutical Preparations><Pharmacogenomics><Phenotype><Population Heterogeneity><Practice Guidelines><Primary Care><Prognosis><Psychological Health><Records><Remission><Reproducibility><Research><Research Design><Sample Size><Sampling><Specialty><Strategic Planning><Structure><Study Type><Substance Use Disorder><Testing><Time><Work><active followup><alternative treatment><analytical method><anti-depressant agent><anti-depressant drugs><anti-depressants><anti-depressive agents><bio-markers><biologic marker><biomarker><clinical applicability><clinical application><clinical phenotype><clinical practice><co-morbid><co-morbidity><comorbidity><customized therapy><customized treatment><data base><data harmonization><data resource><depression symptom><depressive><depressive symptoms><diverse populations><drug/agent><endophenotype><experience><follow up><follow-up><followed up><followup><harmonized data><heterogeneous population><imaging><improved><improved outcome><individualized medicine><individualized patient treatment><individualized therapeutic strategy><individualized therapy><individualized treatment><informatics tool><intervention design><interventional strategy><machine based learning><machine learning based method><machine learning method><machine learning methodologies><medical specialties><medication prescription><next generation><patient specific therapies><patient specific treatment><personalization of treatment><personalized health intervention><personalized intervention><personalized medicine><personalized therapy><personalized treatment><population diversity><precision interventions><predict responsiveness><predicting response><prescribed medication><response><response to therapy><response to treatment><socio-demographics><sociodemographics><study design><substance use and disorder><success><tailored medical treatment><tailored therapy><tailored treatment><therapeutic response><therapy design><therapy response><treatment design><treatment effect><treatment guidelines><treatment pattern><treatment response><treatment responsiveness><unique treatment><unsupervised learning><unsupervised machine learning>